WJ1024/WJ1075, WJ05129, APL1898, and WJ13404 – Junshi Biosciences and Wigen Biomedicine

• Chinese companies Junshi Biosciences and Wigen Biomedicine entered a global development, manufacturing, and commercialization collaboration for Wigen’s four cancer drug candidates

  Drug	MOA	Indication
  APL1898	EGFR-exon20 inhibitor	Unspecified
  WJ1024 or WJ1075	XPO1 inhibitor	Hematological and solid tumors
  WJ05129	Aurora-A inhibitor	SCLC, triple-negative Breast cancer, and other malignant tumors with RB1 deletion or inactivation
  WJ13404	4th generation EGFR inhibitor	Unspecified

• Terms of agreement:
  • Wigen Biomedicine will transfer its 50% interest in four of its self-developed drug projects to Junshi Biosciences
  • Junshi Biosciences will be granted the worldwide exclusive rights for production and commercialization for these drugs
  • Junshi Biosciences and Wigen Biomedicine will jointly facilitate the pre-clinical research work of the above drugs in accordance with the agreement
  • Junshi Biosciences will be responsible for clinical trial applications. Matters such as follow-up clinical trials, drug registration applications, and marketing authorization will be determined by the joint steering committee, which is jointly established by both companies
  • Junshi Biosciences to pay an upfront fee of RMB 36 million to Wigen Biomedicine. Wigen Biomedicine is also eligible to receive milestone payments up to RMB 436 million in aggregate, based on the R&D and commercialization progress, and 50% of net profits